Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma-Reference-Cited by-同舟云学术

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma

Published:2020-02 Issue:2 Volume:13 Page:275-286
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Reger de Moura Coralie,Vercellino Laetitia,Jouenne Fanélie,Baroudjian Barouyr,Sadoux Aurélie,Louveau Baptiste,Delyon Julie,Serror Kevin,Goldwirt Lauriane,Merlet Pascal,Bouquet Fanny,Battistella Maxime,Lebbé Céleste,Mourah Samia

Funder

Fondation de l'Avenir pour la recherche médicale

Institut National de la Santé et de la Recherche Médicale

Société Française de Dermatologie

Roche

Université de Paris

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Improved survival with MEK inhibition in BRAF-mutated melanoma;Flaherty;N Engl J Med,2012

5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models;Melanoma Research;2023-12-22

2. Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge;International Journal of Molecular Sciences;2023-04-26

3. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy;Blood;2022-12-22

4. Intermittent MEK inhibition for the treatment of metastatic uveal melanoma;Frontiers in Oncology;2022-09-29

5. Management of neurofibromatosis type 1-associated plexiform neurofibromas;Neuro-Oncology;2022-06-03